Coronado Biosciences (CNDO) Closes 5.75M Offering at $5/Share
Tweet Send to a Friend
Up)
Coronado Biosciences, Inc. (Nasdaq: CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer, announced today that it closed its previously announced underwritten public offering of 5,750,000 shares of its common stock at a price to the public of $5.00 per share for gross proceeds to Coronado of $28.8 million. The shares include 750,000 shares of common stock sold pursuant to the over-allotment option granted by Coronado to the underwriters, which option was exercised in full. Coronado expects net proceeds of the offering will be approximately $26.5 million, after deducting underwriting commissions and other offering expenses.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Baltic Trading (BALT) to Sell 5.58M Common at $3.60/Share
- J. C. Penney (JCP) Reports Successful Early Tender of 7 1/8% Notes
- NewLead (NEWL) Receives Nasdaq Notice of Non-Compliance Over Late 20-F
Create E-mail Alert Related Categories
Corporate News, Equity Offerings
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
